All data are based on the daily closing price as of October 15, 2026
a

Alfresa Holdings

2784.TSE
14.65 USD
0.30
+2.09%

Overview

Last close
14.65 usd
Market cap
2.57B usd
52 week high
17.15 usd
52 week low
13.19 usd
Target price
14.53 usd

Valuation

P/E
10.5341
Forward P/E
10.0301
Price/Sales
0.1272
Price/Book Value
0.8499
Enterprise Value
1.59B usd
EV/Revenue
0.0808
EV/EBITDA
3.2383

Key financials

Revenue TTM
19.86B usd
Gross Profit TTM
1.39B usd
EBITDA TTM
315.08M usd
Earnings per Share
1.37 usd
Dividend
0.43 usd
Total assets
9.29B usd
Net debt
-996.94M usd

About

Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. The company operates through Wholesale of Prescription Drugs and Related Products, Wholesale of Self-Medication Products, Manufacturing of Pharmaceuticals and Related Products, and Pharmacy and Related Businesses segments. It is also involved in the operation of dispensing pharmacies and conducting related businesses; ethical pharmaceuticals wholesaling business; self-medication products wholesaling business; and other medical-related businesses. In addition, the company manufactures and markets active pharmaceutical ingredients; contract distribution services in hospitals; operation, maintenance, and development of information system; supply of cell raw materials; manufacturing of specific processed cells and regenerative medicine products; and engages in insurance agency, real estate management, and sales of daily necessities and consumables activities. Alfresa Holdings Corporation was incorporated in 2003 and is based in Chiyoda, Japan.
  • Symbol
    2784.TSE
  • Exchange
    TSE
  • Isin
    JP3126340003
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Medical Distribution
  • CEO
  • Headquarter
    Chiyoda
  • Web site
    https://www.alfresa.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top